CJC-1295

CJC-1295 is a lab-made copy of a natural hormone called GHRH (growth hormone-releasing hormone — the signal that tells your body to make growth hormone). It’s built to nudge your body into releasing more of its own growth hormone (GH). Short studies in people confirm it does raise GH and IGF-1 (a growth-related hormone the body makes in response to GH). But no study has shown it actually changes anyone’s health or performance, and no version of it is FDA-approved.

What it is

CJC-1295 is a tweaked copy of the first 29 building blocks (amino acids) of natural GHRH, with four of those building blocks swapped out so the body breaks it down more slowly. A company called ConjuChem developed it in the early 2000s. It comes in two versions.

The “with DAC” version (DAC stands for Drug Affinity Complex) carries an extra chemical piece that latches onto albumin, a protein in the blood. That grip keeps it around far longer — an estimated half-life (the time it takes for half a dose to clear the body) of roughly 6-8 days. The “without DAC” version, usually sold as Modified GRF 1-29, is gone within minutes.

Either way, both versions work the same basic way: they attach to GHRH receptors (docking spots) in the pituitary gland, which then releases GH, which in turn raises IGF-1.

The claims

Sellers pitch CJC-1295 (often paired with another peptide, ipamorelin) for building muscle, losing fat, sleeping better, recovering faster, slowing aging, and improving skin. Here’s the catch: those promises are guesses based on what GH and IGF-1 are known to do in general. They don’t come from studies that actually measured any of those results.

What the evidence actually shows

The main human data come from two carefully run trials — randomized, placebo-controlled, and double-blind (meaning neither the participants nor the researchers knew who got the real drug, the gold standard for cutting out bias). Both were in healthy adults and were reported together by Teichman and colleagues in 2006: one tested single, gradually rising doses, and the other tested repeated doses.

A single shot raised GH roughly 2- to 10-fold for six days or more, and raised IGF-1 about 1.5- to 3-fold for 9-11 days. Repeated dosing kept IGF-1 above its starting level for up to 28 days. So on the lab numbers, the drug does exactly what it’s advertised to do.

But here’s the gap that matters: these were short studies that only measured hormone levels in the blood — not real-world results. No published human trial shows that CJC-1295 actually builds muscle, burns fat, improves sleep, speeds recovery, or treats any condition. A Phase 2 program looking at HIV-related fat redistribution got started but stopped before it could answer any of those questions (more on that below). So the claims about body shape, sleep, and aging simply aren’t backed by direct human evidence.

Legal and regulatory status

The FDA has not approved CJC-1295 for anything, and its development as a drug was abandoned. It was proposed for the FDA’s 503A list — substances that pharmacies are allowed to compound (custom-mix into medications) — but it was placed in Category 2, meaning significant safety concerns and not allowed for compounding.

In December 2024, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed CJC-1295 and voted against adding it to the allowed 503A list. They pointed to concerns including effects on the heart, immunogenicity (the chance the drug triggers an unwanted immune reaction), and thin clinical evidence. The FDA’s background materials for that review also described troubling animal findings, including reported DNA damage in pituitary cells.

During a broader 2026 shake-up of the Category 2 list, the substance’s exact status has been reported inconsistently. But the key points aren’t in dispute: it was never moved to Category 1 (the allowed list), and it’s not among the seven peptides PCAC is set to review at its July 23-24, 2026 meeting. In plain terms, there’s no clear legal path to compound it, and it’s mostly sold gray-market as a “research chemical.”

For athletes, the World Anti-Doping Agency bans GHRH analogues, and names CJC-1295 specifically, at all times — both in and out of competition — under category S2.

Safety

Human safety data are thin and only cover the short term. In the 2006 trials, doses around 30-60 µg/kg were described as safe and reasonably well tolerated, with no serious bad reactions reported; the most commonly noted effect was reactions at the injection site.

The biggest red flag comes from the Phase 2 lipodystrophy study (lipodystrophy is abnormal shifting of body fat) that was shut down. It had enrolled 192 participants and was halted in 2006 after one participant died. The trial physician reportedly attributed the death to pre-existing, silent coronary artery disease (clogged heart arteries the person didn’t know about) with a ruptured plaque, and considered it likely unrelated to the drug — but the trial was ended as a precaution anyway.

Separately, the FDA’s animal-study materials flagged adverse findings for CJC-1295, including reported DNA damage in pituitary cells. Beyond all this, no one really knows the long-term risks of keeping GH and IGF-1 elevated over time in people. And gray-market products add their own problems around purity, dosing, and sterility (whether the product is actually clean and germ-free).

Bottom line

CJC-1295 reliably raises GH and IGF-1 in short human trials, but no study shows it delivers any real health or physique benefit. Its long-term safety is unknown, it’s not FDA-approved, and it’s banned in sport. The marketing is running far ahead of what the evidence can back up.

Evidence grade: 6/10 · Preliminary.

Sources

• Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006.
• CJC-1295 - Wikipedia (development history, DAC vs no-DAC, discontinuation after trial death and reported cause)
• Lipodystrophy study halted after patient death - aidsmap (ConjuChem Phase 2, 192 participants, halted July 2006)
• FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings - Orrick (2026)
• Federal Register: Pharmacy Compounding Advisory Committee; Notice of Meeting (503A bulk drug substances, 2026)
• July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - FDA
• The Prohibited List - World Anti-Doping Agency (S2: GHRH analogues including CJC-1295 prohibited at all times)